|
| Prescription | Design | Sample size | Interventions | Main outcomes | References |
|
| Gushen Antai pill | RCT | 83 | Treatment group: estradiol valerate + Gushen Antai pill | 1. Total efficiency: treatment group—84.85% (28/33); control group—68.00% (34/50) | [29] |
| Control group: estradiol valerate | 2. Endometrial thickness after treatment: treatment group—0.73 ± 0.16 mm; control group—0.88 ± 0.18 mm |
|
| Bushen Huoxue recipe | RCT | 60 | Treatment group: estradiol valerate + Bushen Huoxue recipe | 1. Pregnancy rate: treatment group—43.3% (13/30); control group—26.7 (8/30) | [30] |
| Control group: estradiol valerate | 2. Endometrial thickness after treatment: treatment group—9.6 ± 1.0 mm; control group—8.2 ± 0.4 mm |
|
| Bushen Yanggong decoction | RCT | 120 | Treatment group: Femoston + Bushen Yanggong decoction | 1. Pregnancy rate: treatment group—53.33% (32/60); control group—31.67% (19/60) | [31] |
| Control group: Femoston | 2. Endometrial thickness after treatment: treatment group—8.19 ± 0.83 mm; control group—7.17 ± 0.82 mm |
|
| Bubao decoction | RCT | 115 | Treatment group: Bubao decoction + aspirin enteric-coated aspirin group | 1. Clinical pregnancy rate: treatment group—47.62%; aspirin group—32.56% | [34] |
| Control group | 2. Endometrial thickness after treatment: treatment group—10.65 ±3.03 mm; aspirin group—8.87 ± 2.50 mm |
|
| Danyu decoction | RCT | 50 | Treatment group: Danyu decoction | 1. Pregnancy rate: treatment group—60%; control group—28% | [37] |
| Control group: vitamin E capsule | 2. The rate of type A endometrium: treatment group—84%; control group—68% |
| 3. Treatment group: RI—0.55 ± 0.08; PI—1.83 ± 0.61; control group: RI—0.64 ± 0.16; PI—2.19 ± 0.54 |
|
| Jieyuyubao pills | RCT | 107 | Treatment group: Jieyuyubao pills + clomiphene citrate | 1. Pregnancy rate: treatment group—24.07%; control group—11.32% | [38] |
| 2. The rate of type A endometrium: treatment group—53.7%; control group—35.8% |
| Control group: clomiphene citrate | 3. Symptom scores: treatment group—2.1 ± 0.6; control group—5.1 ± 0.6 |
|
| Erzhi Tiangui granule | RCT | 66 | Treatment group: Erzhi Tiangui granule + gonadotropin therapy | 1. Clinical pregnancy rate: treatment group—54.55% (18/33); control group: 30.30% (10/33) | [39] |
| Control group: gonadotropin therapy + placebo granules | 2. Endometrial DNMT1 expression: treatment group—3.31 ± 0.46; control group—2.97 ± 0.49 |
|
| Yulin Zhuyun prescription | RCT | 150 | Combine group: Yulin Zhuyun prescription + clomifene citrate capsules | 1. Clinical pregnancy rate: combine group—59.1% (26/44); CHM group—44.2% (19/43); Western medicine group—26.8% (11/41) | [40] |
| CHM group: Yulin Zhuyun prescription | 2. Integrin αvβ3: combine group—13.1 ± 2.67; CHM group—13.82 ± 2.04; Western medicine group—7.05 ± 1.37 |
| Western medicine group: Clomifene citrate capsules | 3. GLUT4: combine group—146.82 ± 21.84; CHM group—113.64 ± 15.62; Western medicine group—112.92 ± 18.54 |
|
| Kuntai capsule | RCT | 71 | Treatment group: Kuntai capsule + clomiphene | 1. Pregnancy rate: treatment group—25% (9/36); control group—11.4% (4/35) | [41] |
| Control group: placebo + clomiphene | 2. Integrin β3: treatment group—1.78 ± 0.226; control group—1.46 ± 0.252 |
|
| Wenjing Quyu prescription | RCT | 72 | Treatment group: Wenjing Quyu prescription + Gn + HCG | 1. Pregnancy rate: treatment group—59.38% (19/32); control group—12.96% (7/24) | [45] |
| Control group: Gn + HCG | 2. Covered pinopode area: treatment group—>50%; control group—<20% |
|
| Huayu Xiaozheng prescription | RCT | 60 | Treatment group: Huayu Xiaozheng prescription + urofollicle-stimulating hormone + chorionic gonadotropin + letrozole | 1. Pregnancy rate: treatment group—60% (18/30); control group—33.33% (10/30) | [52] |
| Control group: urofollicle-stimulating hormone + chorionic gonadotropin + letrozole | 2. Uterine volume: treatment group—100.27 ± 2.13 cm3; control group—102.47 ± 3.90 cm3 |
| 3. Endometrial thickness after treatment: treatment group—9.89 ± 044 mm; control group—8.04 ± 1.28 mm |
|
| Yishen Sanjie Quyu decoction | RCT | 102 | Treatment group: Yishen Sanjie Quyu decoction | 1. Uterine volume: treatment group—95.46 ± 3.21 cm3; control group—105.44 ± 4.23 cm3 | [54] |
| Control group: Sanjie Zhentong capsule | 2. Symptom scores: treatment group—5.34 ± 1.46; control group—11.21 ± 2.01 |
|
| Wenjing Yangxue decoction | RCT | 70 | Treatment group: Wenjing Yangxue decoction + dydrogesterone tablets + moxibustion | 1. Uterine volume: treatment group—136.47 ± 23.71 cm3; control group—152.38 ± 39.67 cm3 | [55] |
| Control group: dydrogesterone tablets + moxibustion | 2. RI : treatment group—0.63 ± 0.07; control group—0.66 ± 0.05 |
|
| Penning granules | RCT | 58 | Treatment group: Penning granules | 1. Pregnancy rate: treatment group—54.55% (18/33); control group—20% (1/25) | [58] |
| Control group: levofloxacin + metronidazole tablets | 2. CD38 : treatment group—8.89 ± 7.45; control group—20.12 ± 12.35 |
| 3. HIF-1α : treatment group—1.44 ± 0.95; control group—2.55 ± 1.40 |
|
